{"id":331422,"date":"2026-10-29T11:33:36","date_gmt":"2026-10-29T06:03:36","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=331422"},"modified":"2026-10-29T11:33:36","modified_gmt":"2026-10-29T06:03:36","slug":"midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/","title":{"rendered":"4 Midcap Kotak Mutual Fund Stocks to Watch for Future Multibagger Potential: Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Dixon Rs 11,400. Oberoi Realty Rs 1,601. Radico Khaitan Rs 4,135.10. Ajanta Pharma Rs 3,459.80. Market caps from Rs 43,550 crore to Rs 77,049 crore. Data as of 28 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma are the 4 picks in this Kotak mutual fund stocks watchlist, with market caps between Rs 43,550 crore and Rs 77,049 crore. Dixon stands out for the highest return on equity at 30.76%, while Oberoi Realty offers the lowest PE of the group at 22.90. PE ratios run from 22.90 to 82.61, so compare each one with its industry PE before investing. All figures are as of 28 October 2026.<\/p>\n<\/p><\/div>\n<p>Kotak mutual fund stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma meet that test, with market caps from Rs 43,550 crore to Rs 77,049 crore and Dixon offering the highest return on equity at 30.76%. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and Kotak Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.<\/p>\n<p>This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and Kotak Mutual Fund or one of its schemes listed among its top domestic institutional holders, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening Kotak mutual fund stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 28 October 2026 and are drawn from NSE and BSE data and company filings.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=kotak-mutual-fund-stocks\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#What_Are_Kotak_Mutual_Fund_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\" title=\"What Are Kotak Mutual Fund Stocks and Why Do They Attract Multibagger Interest?\">What Are Kotak Mutual Fund Stocks and Why Do They Attract Multibagger Interest?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Kotak_Mutual_Fund_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\" title=\"Kotak Mutual Fund Stocks at a Glance: Price, Market Cap, PE and ROE\">Kotak Mutual Fund Stocks at a Glance: Price, Market Cap, PE and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Dixon_7144_Profit_CAGR_Since_FY22\" title=\"Dixon: 71.44% Profit CAGR Since FY22\">Dixon: 71.44% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Oberoi_Realty_2440_Profit_CAGR_Since_FY22\" title=\"Oberoi Realty: 24.40% Profit CAGR Since FY22\">Oberoi Realty: 24.40% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Radico_Khaitan_2488_Profit_CAGR_Since_FY22\" title=\"Radico Khaitan: 24.88% Profit CAGR Since FY22\">Radico Khaitan: 24.88% Profit CAGR Since FY22<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Ajanta_Pharma_Return_on_Equity_of_2333\" title=\"Ajanta Pharma: Return on Equity of 23.33%\">Ajanta Pharma: Return on Equity of 23.33%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Kotak_Mutual_Fund_Stocks_Financial_Comparison_on_Growth_and_Margins\" title=\"Kotak Mutual Fund Stocks: Financial Comparison on Growth and Margins\">Kotak Mutual Fund Stocks: Financial Comparison on Growth and Margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Institutional_Holding_in_Dixon_Oberoi_Realty_Radico_Khaitan_and_Ajanta_Pharma\" title=\"Institutional Holding in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma\">Institutional Holding in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Risks_to_Weigh_in_Kotak_Mutual_Fund_Stocks\" title=\"Risks to Weigh in Kotak Mutual Fund Stocks\">Risks to Weigh in Kotak Mutual Fund Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#How_to_Choose_Between_Kotak_Mutual_Fund_Stocks\" title=\"How to Choose Between Kotak Mutual Fund Stocks\">How to Choose Between Kotak Mutual Fund Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Frequently_Asked_Questions_on_Kotak_Mutual_Fund_Stocks_to_Watch\" title=\"Frequently Asked Questions on Kotak Mutual Fund Stocks to Watch\">Frequently Asked Questions on Kotak Mutual Fund Stocks to Watch<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Which_are_the_best_Kotak_mutual_fund_stocks_to_watch_for_multibagger_potential\" title=\"Which are the best Kotak mutual fund stocks to watch for multibagger potential?\">Which are the best Kotak mutual fund stocks to watch for multibagger potential?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Is_Dixon_a_good_stock_for_long-term_investors\" title=\"Is Dixon a good stock for long-term investors?\">Is Dixon a good stock for long-term investors?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Can_Radico_Khaitan_become_a_multibagger_from_here\" title=\"Can Radico Khaitan become a multibagger from here?\">Can Radico Khaitan become a multibagger from here?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#What_is_the_market_cap_of_Dixon_Oberoi_Realty_Radico_Khaitan_and_Ajanta_Pharma\" title=\"What is the market cap of Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?\">What is the market cap of Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#What_are_the_risks_of_investing_in_Kotak_mutual_fund_stocks\" title=\"What are the risks of investing in Kotak mutual fund stocks?\">What are the risks of investing in Kotak mutual fund stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#Why_is_Radico_Khaitan_trading_at_a_PE_of_8261\" title=\"Why is Radico Khaitan trading at a PE of 82.61?\">Why is Radico Khaitan trading at a PE of 82.61?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/midcap-kotak-mutual-fund-stocks-to-watch-multibagger-potential\/#How_much_do_institutions_hold_in_Dixon_Oberoi_Realty_Radico_Khaitan_and_Ajanta_Pharma\" title=\"How much do institutions hold in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?\">How much do institutions hold in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Kotak_Mutual_Fund_Stocks_and_Why_Do_They_Attract_Multibagger_Interest\"><\/span><strong>What Are Kotak Mutual Fund Stocks and Why Do They Attract Multibagger Interest?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kotak mutual fund stocks are shares of mid sized companies in which Kotak Mutual Fund or one of its schemes is named among the top domestic institutional holders in the latest shareholding pattern. The four here cover electronics manufacturing, real estate, spirits and pharmaceuticals.<\/p>\n<p>When a leading fund house like Kotak Mutual Fund holds a large stake, it shows that its research teams have studied the business closely and backed it with investors money. For Kotak mutual fund stocks, both FY26 and the latest quarter showed growth. A sensible way to study Kotak mutual fund stocks is to look at profit growth, returns and valuation side by side. Below, each of Kotak mutual fund stocks gets its own breakdown of growth, returns and valuation. Treat Kotak mutual fund stocks as a research list, since share prices and rankings change with every earnings season.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kotak_Mutual_Fund_Stocks_at_a_Glance_Price_Market_Cap_PE_and_ROE\"><\/span><strong>Kotak Mutual Fund Stocks at a Glance: Price, Market Cap, PE and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Prices are closing prices as of 28 October 2026. Oberoi Realty has the lowest PE of the group at 22.90, while Dixon posts the highest return on equity at 30.76%.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Industry PE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">ROE<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Debt to Equity<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">52-Week Range (Rs)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/dixon\/dixon-technologies-(india)-ltd-share-price-today\">Dixon Technologies<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">11,400<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">77,049<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">37.01<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">45.19<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">30.76%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.21<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">9,600.00 to 17,299.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/oberoirlty\/oberoi-realty-ltd-share-price-today\">Oberoi Realty<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,601<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">60,195<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">22.90<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">31.94<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.99%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.16<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,391.20 to 1,986.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/radico\/radico-khaitan-ltd-share-price-today\">Radico Khaitan<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">4,135.10<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">58,126<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">82.61<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">54.95<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.23%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.15<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,500.00 to 4,747.00<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">3,459.80<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">43,550<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">38.37<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">36.35<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.33%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">0.06<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,380.20 to 3,796.00<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Dixon_7144_Profit_CAGR_Since_FY22\"><\/span><strong>Dixon: 71.44% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Dixon Technologies is an electronics manufacturing services company that makes televisions, phones, appliances and lighting for brands. It reported FY26 revenue of Rs 49,585.84 crore, up 27.53% year on year, and net profit of Rs 1,644.25 crore, up 33.40%. Net profit has compounded at 71.44% a year since FY22, while revenue has grown 46.72% a year. Operating margin was 3.95% in FY26. The debt-to-equity ratio is 0.21.<\/p>\n<p>In the June 2026 quarter, revenue rose 25.23% to Rs 16,075.95 crore and net profit grew 156.35% to Rs 717.83 crore. The share price has gained 114.81% over five years. The stock trades at a PE of 37.01 against an industry PE of 45.19, below the sector average, with a return on equity of 30.76%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Oberoi_Realty_2440_Profit_CAGR_Since_FY22\"><\/span><strong>Oberoi Realty: 24.40% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Oberoi Realty develops premium residential, office, retail and hotel projects, mainly in Mumbai. It reported FY26 revenue of Rs 6,304.27 crore, up 15.16% year on year, and net profit of Rs 2,507.43 crore, up 12.67%. Net profit has compounded at 24.40% a year since FY22, while revenue has grown 23.02% a year. Operating margin was 60.69% in FY26. The debt-to-equity ratio is 0.16.<\/p>\n<p>The stock trades at a PE of 22.90 against an industry PE of 31.94, below the sector average, with a return on equity of 13.99%. In the June 2026 quarter, revenue rose 26.79% to Rs 1,361.69 crore and net profit grew 29.02% to Rs 543.51 crore. The share price has gained 93.04% over five years. Domestic institutions raised their holding from 10.80% in June 2025 to 14.83% in June 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Radico_Khaitan_2488_Profit_CAGR_Since_FY22\"><\/span><strong>Radico Khaitan: 24.88% Profit CAGR Since FY22<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Radico Khaitan makes Indian-made foreign liquor and premium spirits, with brands including Magic Moments, 8PM and Rampur Single Malt. It reported FY26 revenue of Rs 6,062.27 crore, up 24.84% year on year, and net profit of Rs 604.48 crore, up 74.90%. Net profit has compounded at 24.88% a year since FY22, while revenue has grown 20.50% a year. Operating margin was 4.88% in FY26. The debt-to-equity ratio is 0.15, which keeps interest costs low.<\/p>\n<p>In the June 2026 quarter, revenue rose 10.44% to Rs 5,869.46 crore and net profit grew 75.91% to Rs 229.60 crore. The share price has gained 299.58% over five years and 51.47% over the past year. Domestic institutions raised their holding from 25.47% in September 2025 to 27.17% in September 2026. The stock trades at a PE of 82.61 against an industry PE of 54.95, with a return on equity of 18.23%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ajanta_Pharma_Return_on_Equity_of_2333\"><\/span><strong>Ajanta Pharma: Return on Equity of 23.33%<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Ajanta Pharma sells branded generics in ophthalmology, dermatology, cardiology and pain management in India, Africa and Asia. It reported FY26 revenue of Rs 5,624.93 crore, up 18.60% year on year, and net profit of Rs 1,056 crore, up 14.73%. Net profit has compounded at 10.33% a year since FY22, while revenue has grown 12.94% a year. Operating margin was 28.74% in FY26. The debt-to-equity ratio is 0.06, which keeps interest costs low.<\/p>\n<p>The stock trades at a PE of 38.37 against an industry PE of 36.35, with a return on equity of 23.33%. In the June 2026 quarter, revenue rose 27.68% to Rs 1,696.86 crore and net profit grew 30.89% to Rs 334.22 crore. The share price has gained 125.31% over five years and 35.42% over the past year. Domestic institutions raised their holding from 17.90% in September 2025 to 21.94% in September 2026.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kotak_Mutual_Fund_Stocks_Financial_Comparison_on_Growth_and_Margins\"><\/span><strong>Kotak Mutual Fund Stocks: Financial Comparison on Growth and Margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table compares scale and growth across these Kotak mutual fund stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Revenue Growth (YoY)<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Revenue CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">4-Year Net Profit CAGR<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Operating Margin (Latest Quarter)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dixon<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">49,585.84<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,644.25<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.53%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">46.72%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">71.44%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.43%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Oberoi Realty<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6,304.27<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2,507.43<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.16%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.02%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.40%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">61.42%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Radico Khaitan<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6,062.27<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">604.48<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.84%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">20.50%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">24.88%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.10%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">5,624.93<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">1,056<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.60%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">12.94%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">10.33%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">30.41%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data on these Kotak mutual fund stocks<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Institutional_Holding_in_Dixon_Oberoi_Realty_Radico_Khaitan_and_Ajanta_Pharma\"><\/span><strong>Institutional Holding in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional holding shows who is backing these Kotak mutual fund stocks alongside the promoter. The table uses the latest reported quarter for each. Dixon has the deepest institutional backing, with FII and DII together holding 47.67% as of September 2026. Domestic institutions increased their holding over the past year in Oberoi Realty (from 10.80% to 14.83%), Radico Khaitan (from 25.47% to 27.17%) and Ajanta Pharma (from 17.90% to 21.94%).<\/p>\n<table style=\"border-collapse:collapse;width:100%;margin:16px 0;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Stock<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Promoter<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">FII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">DII<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Public<\/th>\n<th style=\"border:1px solid #BBBBBB;background:#1F4E79;color:#FFFFFF;padding:8px;text-align:left;\">Quarter<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Dixon<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.50%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">18.96%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">28.71%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">23.83%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Oberoi Realty<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">67.70%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">15.11%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">14.83%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">2.36%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">June 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Radico Khaitan<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">40.17%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">19.43%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">27.17%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">13.23%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">63.47%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">7.63%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">21.94%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">6.96%<\/td>\n<td style=\"border:1px solid #BBBBBB;padding:8px;\">September 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Weigh_in_Kotak_Mutual_Fund_Stocks\"><\/span><strong>Risks to Weigh in Kotak Mutual Fund Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Being careful with Kotak mutual fund stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:<\/p>\n<ul>\n<li>Past growth may not repeat.<\/li>\n<li>Share prices can move sharply in either direction.<\/li>\n<li><strong>Valuation:<\/strong> Radico Khaitan trades at a PE of 82.61 against an industry PE of 54.95, so earnings need to keep growing to support the price.<\/li>\n<li><strong>Concentration:<\/strong> Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Choose_Between_Kotak_Mutual_Fund_Stocks\"><\/span><strong>How to Choose Between Kotak Mutual Fund Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Picking from Kotak mutual fund stocks comes down to four checks, applied in order.<\/p>\n<ol>\n<li>Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.<\/li>\n<li>Compare each PE with the industry PE (31.94 to 54.95) and ask whether the growth rate justifies any gap.<\/li>\n<li>Track net profit growth, the operating margin and the return on equity in every quarterly result.<\/li>\n<li>Stagger entries across quarters and review institutional holding every reporting season.<\/li>\n<\/ol>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among Kotak mutual fund stocks, Dixon stands out for the highest return on equity at 30.76%, Oberoi Realty for the lowest PE of the group at 22.90, Radico Khaitan for the biggest five-year price gain at 299.58% and Ajanta Pharma for a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing Kotak mutual fund stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Kotak_Mutual_Fund_Stocks_to_Watch\"><\/span><strong>Frequently Asked Questions on Kotak Mutual Fund Stocks to Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_are_the_best_Kotak_mutual_fund_stocks_to_watch_for_multibagger_potential\"><\/span><strong>Which are the best Kotak mutual fund stocks to watch for multibagger potential?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma are the 4 names this list highlights, with market caps of Rs 77,049 crore, Rs 60,195 crore, Rs 58,126 crore and Rs 43,550 crore respectively. Dixon is notable for the highest return on equity at 30.76%. Oberoi Realty stands out for the lowest PE of the group at 22.90. Radico Khaitan offers the biggest five-year price gain at 299.58%. Ajanta Pharma brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. These are watchlist names for Kotak mutual fund stocks, not recommendations, so match each one to your own risk profile and time horizon.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Dixon_a_good_stock_for_long-term_investors\"><\/span><strong>Is Dixon a good stock for long-term investors?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dixon has a return on equity of 30.76%, a PE of 37.01 against an industry PE of 45.19 and a market cap of Rs 77,049 crore. Net profit has compounded at 71.44% a year since FY22, and FY26 revenue rose 27.53% while June 2026 quarter net profit grew 156.35%. Long-term returns in Kotak mutual fund stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Can_Radico_Khaitan_become_a_multibagger_from_here\"><\/span><strong>Can Radico Khaitan become a multibagger from here?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Radico Khaitan has already gained 299.58% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Kotak mutual fund stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.88% a year since FY22, and FY26 revenue rose 24.84%. At a PE of 82.61 against an industry PE of 54.95, valuation should be checked against that growth before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_of_Dixon_Oberoi_Realty_Radico_Khaitan_and_Ajanta_Pharma\"><\/span><strong>What is the market cap of Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 28 October 2026, Dixon has a market cap of Rs 77,049 crore, Oberoi Realty has a market cap of Rs 60,195 crore, Radico Khaitan has a market cap of Rs 58,126 crore and Ajanta Pharma has a market cap of Rs 43,550 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Kotak mutual fund stocks.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_of_investing_in_Kotak_mutual_fund_stocks\"><\/span><strong>What are the risks of investing in Kotak mutual fund stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Radico Khaitan trades at a PE of 82.61 against an industry PE of 54.95, so earnings growth needs to hold up.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Radico_Khaitan_trading_at_a_PE_of_8261\"><\/span><strong>Why is Radico Khaitan trading at a PE of 82.61?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Radico Khaitan&#8217;s PE of 82.61 compares with an industry PE of 54.95. The market is paying a premium for a return on equity of 18.23%, profit growth of 24.88% a year since FY22 and latest-quarter profit growth of 75.91%, which also means the stock is more sensitive if growth slows. Investors in Kotak mutual fund stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_do_institutions_hold_in_Dixon_Oberoi_Realty_Radico_Khaitan_and_Ajanta_Pharma\"><\/span><strong>How much do institutions hold in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of the latest reported quarter, FII and DII together hold 47.67% of Dixon (18.96% and 28.71%), 29.94% of Oberoi Realty (15.11% and 14.83%), 46.60% of Radico Khaitan (19.43% and 27.17%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in Kotak mutual fund stocks, though it should be read with earnings trends rather than on its own.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which are the best Kotak mutual fund stocks to watch for multibagger potential?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma are the 4 names this list highlights, with market caps of Rs 77,049 crore, Rs 60,195 crore, Rs 58,126 crore and Rs 43,550 crore respectively. Dixon is notable for the highest return on equity at 30.76%. Oberoi Realty stands out for the lowest PE of the group at 22.90. Radico Khaitan offers the biggest five-year price gain at 299.58%. Ajanta Pharma brings a nearly debt-free balance sheet, with a debt-to-equity ratio of 0.06. These are watchlist names for Kotak mutual fund stocks, not recommendations, so match each one to your own risk profile and time horizon.\"}},{\"@type\":\"Question\",\"name\":\"Is Dixon a good stock for long-term investors?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dixon has a return on equity of 30.76%, a PE of 37.01 against an industry PE of 45.19 and a market cap of Rs 77,049 crore. Net profit has compounded at 71.44% a year since FY22, and FY26 revenue rose 27.53% while June 2026 quarter net profit grew 156.35%. Long-term returns in Kotak mutual fund stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.\"}},{\"@type\":\"Question\",\"name\":\"Can Radico Khaitan become a multibagger from here?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Radico Khaitan has already gained 299.58% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in Kotak mutual fund stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.88% a year since FY22, and FY26 revenue rose 24.84%. At a PE of 82.61 against an industry PE of 54.95, valuation should be checked against that growth before investing.\"}},{\"@type\":\"Question\",\"name\":\"What is the market cap of Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 28 October 2026, Dixon has a market cap of Rs 77,049 crore, Oberoi Realty has a market cap of Rs 60,195 crore, Radico Khaitan has a market cap of Rs 58,126 crore and Ajanta Pharma has a market cap of Rs 43,550 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on Kotak mutual fund stocks.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks of investing in Kotak mutual fund stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Radico Khaitan trades at a PE of 82.61 against an industry PE of 54.95, so earnings growth needs to hold up.\"}},{\"@type\":\"Question\",\"name\":\"Why is Radico Khaitan trading at a PE of 82.61?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Radico Khaitan's PE of 82.61 compares with an industry PE of 54.95. The market is paying a premium for a return on equity of 18.23%, profit growth of 24.88% a year since FY22 and latest-quarter profit growth of 75.91%, which also means the stock is more sensitive if growth slows. Investors in Kotak mutual fund stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.\"}},{\"@type\":\"Question\",\"name\":\"How much do institutions hold in Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of the latest reported quarter, FII and DII together hold 47.67% of Dixon (18.96% and 28.71%), 29.94% of Oberoi Realty (15.11% and 14.83%), 46.60% of Radico Khaitan (19.43% and 27.17%) and 29.57% of Ajanta Pharma (7.63% and 21.94%). Rising institutional holding is a useful signal in Kotak mutual fund stocks, though it should be read with earnings trends rather than on its own.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>4 midcap Kotak mutual fund stocks compared on market cap, PE, ROE, growth and institutional holding: Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma.<\/p>\n","protected":false},"author":33,"featured_media":331421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[17651,17650],"class_list":["post-331422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-kotak-mutual-fund-sector","tag-kotak-mutual-fund-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["331421"],"rank_math_title":["Kotak Mutual Fund Stocks 2026: Dixon, Oberoi Realty"],"rank_math_description":["Kotak mutual fund stocks to watch for multibagger potential: Dixon, Oberoi Realty, Radico Khaitan and Ajanta Pharma. Compare market cap, PE, ROE and growth."],"rank_math_focus_keyword":["Kotak mutual fund stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/4-midcap-kotak-mutual-fund-stocks-to-watch-for-future-multibagger-potential.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=331422"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331422\/revisions"}],"predecessor-version":[{"id":331423,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/331422\/revisions\/331423"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/331421"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=331422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=331422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=331422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}